Evidence map›Paper›PMID 37684337›Full record

ArticleCommunications biology2023

The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy.

Amr Ali, Bassem Mekhaeil, Olga-Demetra Biziotis, Evangelia E Tsakiridis, Elham Ahmadi, Jianhan Wu, Simon Wang, Kanwaldeep Singh, Gabe Menjolian, Thomas Farrell and 6 more

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 3 pooled it
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Metabolic convergence of diabetes and prostate cancer: from dysglycemia to tumor microenvironment reprogramming.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Amr AliDepartments of Oncology, McMaster University, Hamilton, ON, Canada.ORCID http://orcid.org/0000-0002-1750-0605
Bassem MekhaeilDepartments of Oncology, McMaster University, Hamilton, ON, Canada.
Olga-Demetra BiziotisDepartments of Oncology, McMaster University, Hamilton, ON, Canada.ORCID http://orcid.org/0000-0002-7838-5938
Evangelia E TsakiridisCentre for Metabolism, Obesity and Diabetes Research, McMaster University, Hamilton, ON, Canada.
Elham AhmadiDepartments of Oncology, McMaster University, Hamilton, ON, Canada.ORCID http://orcid.org/0000-0003-0472-4615
Jianhan WuCentre for Metabolism, Obesity and Diabetes Research, McMaster University, Hamilton, ON, Canada.
Simon WangDepartments of Oncology, McMaster University, Hamilton, ON, Canada.
Kanwaldeep SinghDepartments of Oncology, McMaster University, Hamilton, ON, Canada.ORCID http://orcid.org/0000-0001-7183-6460
Gabe MenjolianDepartment of Radiotherapy, Juravinski Cancer Center, Hamilton, ON, Canada.
Thomas FarrellDepartment of Physics, Juravinski Cancer Center, Hamilton, Ontario, Canada.
Aruz MesciDepartments of Oncology, McMaster University, Hamilton, ON, Canada.
Stanley LiuOdette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0001-6851-0857
Tobias BergDepartments of Oncology, McMaster University, Hamilton, ON, Canada.ORCID http://orcid.org/0000-0003-2668-0449
Jonathan L BramsonDepartments of Oncology, McMaster University, Hamilton, ON, Canada.ORCID http://orcid.org/0000-0003-2874-6886
Gregory R SteinbergCentre for Metabolism, Obesity and Diabetes Research, McMaster University, Hamilton, ON, Canada.ORCID http://orcid.org/0000-0001-5425-8275
Theodoros TsakiridisDepartments of Oncology, McMaster University, Hamilton, ON, Canada. tsakirt@mcmaster.ca.ORCID http://orcid.org/0000-0002-8675-4422
Discovery Centre · CAMcMaster University · CAJuravinski Cancer Centre · CASunnybrook Health Science Centre · CA

Funding

CIHR
6 · The paper itself

Abstract

Radiotherapy is a non-invasive standard treatment for prostate cancer (PC). However, PC develops radio-resistance, highlighting a need for agents to improve radiotherapy response. Canagliflozin, an inhibitor of sodium-glucose co-transporter-2, is approved for use in diabetes and heart failure, but is also shown to inhibit PC growth. However, whether canagliflozin can improve radiotherapy response in PC remains unknown. Here, we show that well-tolerated doses of canagliflozin suppress proliferation and survival of androgen-sensitive and insensitive human PC cells and tumors and sensitize them to radiotherapy. Canagliflozin blocks mitochondrial respiration, promotes AMPK activity, inhibits the MAPK and mTOR-p70

Indexed as

Heart FailureProstatic NeoplasmsSodium-Glucose Transporter 2 InhibitorsCanagliflozinHumansMaleMitochondriaCanagliflozinSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID37684337
PMCPMC10491589
OpenAlexW4386545412

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.